This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fujimoto, K. Articles by Terada, M. Search for Related Content PubMed PubMed Citation Articles by Fujimoto, K. Articles by Terada, M.

Frequent Association of p53 Gene Mutation in Invasive Bladder Cancer¹

Genetics Division [K. F., Y. Y., H. S., T. S., M. T.], National Cancer Center Research Institute, and Department of Urology [T. K.], National Cancer Center Hospital, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104, and Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634 [K. F., E.O.], Japan

Structural alterations of the p53 gene were investigated to elucidate the molecular biological difference between superficial and invasive bladder cancer by polymerase chain reaction single-strand conformation polymorphism analysis. In 25 bladder cancers obtained from 23 patients, p53 gene mutations were investigated in exon regions 4 to 11. Twenty-four were transitional cell carcinomas, and the remaining one was a squamous cell carcinoma. Only one of 13 superficial bladder cancers, including pTis, pTa, and pT1, was found to have p53 gene mutation. However, of 12 invasive bladder cancers with pT2, pT3, and pT4, six primary carcinomas, including a squamous cell carcinoma and one metastatic carcinoma, were found to have p53 gene mutations. The number of cancers examined in Grades 1, 2, and 3 was three, seven, and 15, respectively. p53 gene mutation was not found in any of the ten cancers with Grades 1 and 2, while eight of 15 bladder cancers with Grade 3 were found to have p53 gene mutation.

The results indicated that the incidence of p53 gene mutations appeared to be much higher in invasive-type and high-grade bladder cancers than in superficial and low-grade ones. Our results are compatible with the recently published results by Sidransky et al. [Science (Washington DC), 252: 706–709, 1991] showing that p53 gene mutations were frequently found in invasive bladder cancers by sequence analysis on polymerase chain reaction amplified products corresponding to exons 5 to 9. Our results are also compatible with previously reported results by Olumi et al. (Cancer Res., 50: 7081–7083, 1990) showing that the loss of chromosome 17p, revealed by analysis with restriction fragment length polymorphism, was frequent in high-grade bladder cancers. In this study, p53 gene mutations were often found in exon 4 as well as in other exons. Therefore, this region should also be examined for screening of mutations of this gene in bladder cancer. There appeared to be no consistent mutation sites in exons 4 to 11 of the p53 gene and no specific patterns of the mutation in bladder cancer.

¹ This study was supported in part by Grants-in-Aid from the Ministry of Health and Welfare for a Comprehensive 10-Year Strategy for Cancer Control, Japan.

² Recipient of a Research Resident Fellowship from the Foundation for Promotion of Cancer Research.

³ To whom requests for reprints should be addressed.

Received 9/ 9/91. Accepted 12/27/91.

This article has been cited by other articles:

				B. George, R. H. Datar, L. Wu, J. Cai, N. Patten, S. J. Beil, S. Groshen, J. Stein, D. Skinner, P. A. Jones, et al. p53 Gene and Protein Status: The Role of p53 Alterations in Predicting Outcome in Patients With Bladder Cancer J. Clin. Oncol., December 1, 2007; 25(34): 5352 - 5358. [Abstract] [Full Text] [PDF]

				E. Lopez-Knowles, S. Hernandez, M. Kogevinas, J. Lloreta, A. Amoros, A. Tardon, A. Carrato, S. Kishore, C. Serra, N. Malats, et al. The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors. Clin. Cancer Res., October 15, 2006; 12(20): 6029 - 6036. [Abstract] [Full Text] [PDF]

				M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF]

				B. Schlichtholz, M. Presler, and M. Matuszewski Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast Carcinogenesis, December 1, 2004; 25(12): 2319 - 2323. [Abstract] [Full Text] [PDF]

				C. Cordon-Cardo p53 and RB: Simple Interesting Correlates or Tumor Markers of Critical Predictive Nature? J. Clin. Oncol., March 15, 2004; 22(6): 975 - 977. [Full Text] [PDF]

				S. J. Chatterjee, R. Datar, D. Youssefzadeh, B. George, P. J. Goebell, J. P. Stein, L. Young, S.-R. Shi, C. Gee, S. Groshen, et al. Combined Effects of p53, p21, and pRb Expression in the Progression of Bladder Transitional Cell Carcinoma J. Clin. Oncol., March 15, 2004; 22(6): 1007 - 1013. [Abstract] [Full Text] [PDF]

				A. A. Bakkar, H. Wallerand, F. Radvanyi, J.-B. Lahaye, S. Pissard, L. Lecerf, J. C. Kouyoumdjian, C. C. Abbou, J.-C. Pairon, M.-C. Jaurand, et al. FGFR3 and TP53 Gene Mutations Define Two Distinct Pathways in Urothelial Cell Carcinoma of the Bladder Cancer Res., December 1, 2003; 63(23): 8108 - 8112. [Abstract] [Full Text] [PDF]

				J. C. Schroeder, K. Conway, Y. Li, K. Mistry, D. A. Bell, and J. A. Taylor p53 Mutations in Bladder Cancer: Evidence for Exogenous versus Endogenous Risk Factors Cancer Res., November 1, 2003; 63(21): 7530 - 7538. [Abstract] [Full Text] [PDF]

				P. Sweeney, T. Karashima, H. Ishikura, S. Wiehle, M. Yamashita, W. F. Benedict, R. J. Cristiano, and C. P. N. Dinney Efficient Therapeutic Gene Delivery after Systemic Administration of a Novel Polyethylenimine/DNA Vector in an Orthotopic Bladder Cancer Model Cancer Res., July 15, 2003; 63(14): 4017 - 4020. [Abstract] [Full Text] [PDF]

				S. Sugiura, K. Ogawa, M. Hirose, F. Takeshita, M. Asamoto, and T. Shirai Reversibility of proliferative lesions and induction of non-papillary tumors in rat urinary bladder treated with phenylethyl isothiocyanate Carcinogenesis, March 1, 2003; 24(3): 547 - 553. [Abstract] [Full Text] [PDF]

				A. Besaratinia, S. E. Bates, and G. P. Pfeifer Mutational Signature of the Proximate Bladder Carcinogen N-Hydroxy-4-acetylaminobiphenyl: Inconsistency with the p53 Mutational Spectrum in Bladder Cancer Cancer Res., August 1, 2002; 62(15): 4331 - 4338. [Abstract] [Full Text] [PDF]

				H. Shiina, M. Igawa, S. Urakami, K. Shigeno, T. Yoneda, M. Terashima, M. Deguchi, L. Ribeiro-Filho, and R. Dahiya Alterations of {beta}- and {gamma}-Catenin in N-Butyl-N-(-4-hydroxybutyl)nitrosamine-induced Murine Bladder Cancer Cancer Res., October 1, 2001; 61(19): 7101 - 7109. [Abstract] [Full Text] [PDF]

				Y. Mori, A. Koide, K. Fuwa, H. Wanibuchi, and S. Fukushima Lack of change in the levels of liver and kidney cytochrome P-450 isozymes in p53(+/-) knockout mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine Mutagenesis, September 1, 2001; 16(5): 377 - 383. [Abstract] [Full Text] [PDF]

				B. W. G. van Rhijn, I. Lurkin, F. Radvanyi, W. J. Kirkels, T. H. van der Kwast, and E. C. Zwarthoff The Fibroblast Growth Factor Receptor 3 (FGFR3) Mutation Is a Strong Indicator of Superficial Bladder Cancer with Low Recurrence Rate Cancer Res., February 1, 2001; 61(4): 1265 - 1268. [Abstract] [Full Text]

				D. A. Delker, B. L. Yano, and B. B. Gollapudi Evaluation of Cytotoxicity, Cell Proliferation, and Genotoxicity Induced by p-Cresidine in Hetero- and Nullizygous Transgenic p53 Mice Toxicol. Sci., June 1, 2000; 55(2): 361 - 369. [Abstract] [Full Text] [PDF]

				K. Mitsumori, H. Onodera, T. Shimo, K. Yasuhara, H. Takagi, T. Koujitani, M. Hirose, C. Maruyama, and S. Wakana Rapid induction of uterine tumors with p53 point mutations in heterozygous p53-deficient CBA mice given a single intraperitoneal administration of N-ethyl-N-nitrosourea Carcinogenesis, May 1, 2000; 21(5): 1039 - 1042. [Abstract] [Full Text] [PDF]

				J. Zhao, J. Richter, U. Wagner, B. Roth, P. Schraml, T. Zellweger, D. Ackermann, U. Schmid, H. Moch, M. J. Mihatsch, et al. Chromosomal Imbalances in Noninvasive Papillary Bladder Neoplasms (pTa) Cancer Res., September 1, 1999; 59(18): 4658 - 4661. [Abstract] [Full Text] [PDF]

				S. Yamamoto, A. Romanenko, M. Wei, C. Masuda, W. Zaparin, W. Vinnichenko, A. Vozianov, C. C. R. Lee, K. Morimura, H. Wanibuchi, et al. Specific p53 Gene Mutations in Urinary Bladder Epithelium after the Chernobyl Accident Cancer Res., August 1, 1999; 59(15): 3606 - 3609. [Abstract] [Full Text] [PDF]

				K. Morimura, S. Yamamoto, T. Murai, S. Mori, T.-X. Chen, H. Wanibuchi, and S. Fukushima LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine Carcinogenesis, April 1, 1999; 20(4): 715 - 718. [Abstract] [Full Text] [PDF]

				M. H. Mostafa, S. A. Sheweita, and P. J. O'Connor Relationship between Schistosomiasis and Bladder Cancer Clin. Microbiol. Rev., January 1, 1999; 12(1): 97 - 111. [Abstract] [Full Text] [PDF]

				R. H. Hruban, P. van der Riet, Y. S. Erozan, and D. Sidransky Molecular Biology and the Early Detection of Carcinoma of the Bladder -- The Case of Hubert H. Humphrey N. Engl. J. Med., May 5, 1994; 330(18): 1276 - 1278. [Full Text]